Dean Richard Artis Sells 5,515 Shares of Annexon, Inc. (NASDAQ:ANNX) Stock

Annexon, Inc. (NASDAQ:ANNX) EVP Dean Richard Artis sold 5,515 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $2.97, for a total transaction of $16,379.55. Following the completion of the sale, the executive vice president now directly owns 83,814 shares in the company, valued at $248,927.58. This trade represents a 6.17 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Annexon Stock Performance

ANNX opened at $2.81 on Friday. The company has a fifty day moving average of $4.26 and a two-hundred day moving average of $5.55. The stock has a market capitalization of $299.52 million, a price-to-earnings ratio of -2.68 and a beta of 1.07. Annexon, Inc. has a fifty-two week low of $2.63 and a fifty-two week high of $8.40.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ANNX. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research report on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price objective on shares of Annexon in a report on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Annexon in a report on Tuesday, December 17th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $15.80.

Institutional Trading of Annexon

Institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new position in shares of Annexon during the 4th quarter worth approximately $59,000. CANADA LIFE ASSURANCE Co purchased a new stake in Annexon in the 4th quarter worth $77,000. E Fund Management Co. Ltd. raised its position in Annexon by 36.0% during the fourth quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after acquiring an additional 4,086 shares during the period. Forefront Analytics LLC lifted its holdings in Annexon by 56.8% during the fourth quarter. Forefront Analytics LLC now owns 16,433 shares of the company’s stock valued at $84,000 after purchasing an additional 5,950 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Annexon in the fourth quarter valued at about $98,000.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.